Genedrive MT-RNR1 ID Kit to detect genetic variation and protect hearing in babies: early value appraisal.
The Genedrive MT-RNR1 ID Kit has potential benefits in identifying babies at risk of hearing loss from aminoglycoside due to the MT-RNR1 m.1555A>G variant, allowing for alternative antibiotics to be used instead. However, managing the risk of early access is important, including ensuring timely antibiotics, avoiding unnecessary use of alternative antibiotics, and confirming positive results. The economic evidence suggests cost-effectiveness, but upfront costs may be high. Data should be generated in centers with babies from different ethnicities to promote equality.
Recent Posts
African Pharmacogenomic Integration Enhancing Essential Medicine Prescribing in Africa
African Pharmacogenomic Integration has become an urgent policy priority, with evidence showing that more than 10 percent of essential medicines across Africa require genetically guided prescribing to prevent harm and improve outcomes in diverse populations. Current dosage guidelines for HIV, ...
Pharmaceutical Manufacturing Affordability as a Key to South Africa’s Local Production Goals
Pharmaceutical manufacturing affordability remains the decisive factor in South Africa’s efforts to build domestic capacity for essential medicines and vaccines. Government, industry and research leaders who met at the TIPS Development Dialogue on 17 June made clear that economic barriers to acce...
Catalysts Driving Portugal Biotech Growth in Europe
Portugal Biotech Growth is reshaping the country’s standing in European life sciences, delivering a compact yet high-potential ecosystem anchored by world-class universities in Porto and Coimbra, innovation parks, and forward-looking industrial policy. Once overshadowed by larger neighbours, Port...